Cytocentrics Bioscience GmbH Cytocentrics Bioscience GmbH is a biotechnology company applying its ion channel expertise to support the pharmaceutical industry in the drug discovery process. Our products are designed to simplify and optimize laboratory productivity. We want to make the drug discovery process more efficient and cost effective while focusing on quality and reliability. Our contribution is to provide cutting-edge solutions to assist drug screening of ion channel targets, especially in early drug profiling and safety pharmacology: Sale of the CytoPatch™ Instrument, an automated patch clamp platform Ion Channel Screening Service: Safety- and Efficacy Screening Execution of GLP Studies Ion Channel Assay Development Development of electrophysiologically validated cell lines Sale of ready-to-use kits with quality-assured cells and buffers as turnkey solution Optimization of cell lines and buffers Cytocentrics Bioscience GmbH was founded in 2001 as a spin-off from the Natural and Medical Sciences Institute at the University of Tuebingen (NMI). The foundation is based upon several years of intensive research of the founders Dr. Thomas Knott and Dr. Alfred Stett. The company has a solid scientific background backed by an experienced management team, outstanding partners and a world-class scientific advisor, Nobel Prize winner Prof. Erwin Neher. Our products and technologies are protected by five patent families and patent applications in the areas of electrophysiology, cell biology and microsystems technology. Cytocentrics’ mission is to become a leading full service provider for pharmaceutical research in the area of ion channel screening.